Physician profile

Corey A Thompson

Foot and Ankle Surgery · Raleigh, NC

NPI 1790906543

$712.28

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$550.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Tricoast Surgical Solutions LLC $282.50 2023
Sanara Medtech INC. $204.17 2023 Celleraterx
Wright Medical Technology, INC. $94.38 2019
Depuy Synthes Sales INC. $34.98 2019
Polarityte, INC. $32.10 2019
Smith+Nephew, INC. $24.90 2024 Stravix Pl, Oasis, Grafix
Abbott Laboratories $20.11 2024 Proclaim
Pacira Pharmaceuticals Incorporated $19.14 2024 Iovera, Exparel

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Corey A Thompson

$712.28

in general payments reported 2019-2025

Years
2019-2024
Top company
Tricoast Surgical Solutions LLC

https://glasscript.com/doctor/784513/corey-a-thompson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.